Table 1 Rubraxanthone efficacy, as determined using cell-based assays. Results are presented as mean ± standard error of the mean (SEM) for three biologically independent experiments.
From: Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO
EC50 (µM) | CC50 (µM) | ||
---|---|---|---|
Vero E6 | Vero E6 | Calu-3 | |
Rubraxanthone | 4.00 ± 1.75 | 26.61 ± 2.95 | > 50 |